Penn Center for AIDS Research

Pablo Tebas

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Universidad Autónoma de Madrid, Spain, 1985.
Post-Graduate Training
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.
Spanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2014.
American Board of Internal Medicine, Infectious Diseases, 2015.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Selected Publications

Varriale, J., Beg, S., McMyn, N., Pui Chan, K.P., Simonetti, F.R., Lynn, K., Tebas, P., Frank, I., Mounzer, K., Bar, K.J., Seaman, M., Siliciano, R., Siliciano, J.: Autologous Neutralization Of HIV Reservoir Outgrowth Is Stable Over Time During ART 29th Conference on Retrovirus and Oppotunistic infections. February 12-16, 2022 Denver, Abstract #372 February 2022.

Caskey, M. , Millard, K., Turroja, M., Gaebler, C., Logue, E., Jiang, C.S. , Todd, L., Reeves, J.D. , Petropoulos, C., Wilkin, T., Tebas, P., Nussenzweig, M. C.: Phase I Study of Long-Acting BNC117 and 10-1074- In Viremic Adults Living With HIV 29th Conference on Retrovirus and Oppotunistic infections. February 12-16, 2022 Denver, Abstract #140 February 2022.

Collora, J.A., Liu, R., Ravindra, N., Pinto-Santini, D.M., Pasalar, S., Ganoza, C., Lama, J.R., Alfaro, R., Spudich, S.S., Mounzer, K., Tebas, P., Montaner, L.J., Van Djik, D., Duerr, A.C., Ho, Y.C.: Single-Cell Multiomics Reveals HIV-1 Persistence In Expanded Cytotoxic T-Cell Clones 29th Conference on Retrovirus and Oppotunistic infections. February 12-16, 2022 Denver, Abstract #69 February 2022.

Hait, S.H., Lovelace, S.E., Coates, E.E., Chen, G., Gaudinski, M.R. , Rothwell, R.S., Donaghy, E., Roa, J., Fichtenbaum, C.J., Santana, J., Presti, R., Tebas, P., Ledgerwood, J.E. , Pegu, A., Mascola,J.R.: Ex Vivo Assay Predicts HIV-1 Suppression BY Bnabs Infused in a Phase I Clinical Trial 29th Conference on Retrovirus and Oppotunistic infections. February 12-16, 2022 Denver, Abstract #287 February 2022.

Montaner, L.J., Lynn, K., Azzoni, L., Papasavvas, E., Fair, M., Cocchella, G., Sciorillo, A. , Kang, C, Reeves, J.D., Lalley-Chareczko, L., Kostman, J.R., Short, W.R., Mounzer, K., Petropoulos. C., Tebas, P.: Susceptibility to 3BNC117 and 10-1074 In ART-Suppressed Chronically Infected Persons. 29th Conference on Retrovirus and Oppotunistic infections. February 12-16, 2022 Denver, Abstract #503 February 2022.

Tebas, P., Azzoni, L., Papasavvas,E., Choi,G., Ellenberg,S.S., Caskey,M., Howell,B., Hazuda,D., Petropoulos,C., Lynn,K., Lalley-Chareczko,L., Kostman,J.R., Short,W.R., Mounzer,K., Montaner,L.J.: BEAT2: Peg-Ifn-Α2b + 3BNC117 And 10-1074 Keeps HIV At <20 C/ml During 26 week ATI. 29th Conference on Retrovirus and Oppotunistic infections. February 12-16, 2022 Denver, Abstract #352 February 2022.

Solomon, S. S., Wagner-Cardoso, S., Smeaton, L., Sowah, L. A., Wimbish, C., Robbins, G., Brates, I., Scello, C., Son, A., Avihingsanon, A., Linas, B., Anthony, D., Nunes, E. P., Kliemann, D. A., Supparatpinyo, K., Kityo, C., Tebas, P., Bennet, J. A., Santana-Bagur, J., Benson, C. A., Van Schalkwyk, M., Cheinquer, N., Naggie, S., Wyles, D., Sulkowski, M.: A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol January 2022.

Kraynyak, K. A., Blackwood, E., Agnes, J., Tebas, P., Giffear, M., Amante, D., Reuschel, E. L., Purwar, M., Christensen-Quick, A., Liu, N., Andrade, V. M., Diehl, M. C., Wani, S., Lupicka, M., Sylvester, A., Morrow, M. P., Pezzoli, P., McMullan, T., Kulkarni, A. J., Zaidi, F. I., Frase, D., Liaw, K., Smith, T. R. F., Ramos, S. J., Ervin, J., Adams, M., Lee, J., Dallas, M., Brown, A. S., Shea, J. E., Kim, J. J., Weiner, D. B., Broderick, K. E., Humeau, L. M., Boyer, J. D., Mammen, M. P.: SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. J Infect Dis January 2022.

Troxel, A. B., Petkova, E., Goldfeld, K., Liu, M., Tarpey, T., Wu, Y., Wu, D., Agarwal, A., Avendano-Sola, C., Bainbridge, E., Bar, K. J., Devos, T., Duarte, R. F., Gharbharan, A., Hsue, P. Y., Kumar, G., Luetkemeyer, A. F., Meyfroidt, G., Nicola, A. M., Mukherjee, A., Ortigoza, M. B., Pirofski, L. A., Rijnders, B. J. A., Rokx, C., Sancho-Lopez, A., Shaw, P., Tebas, P., Yoon, H. A., Grudzen, C., Hochman, J., Antman, E. M.: Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. JAMA Netw Open 5(1): e2147331, January 2022.

Bar, K. J., Shaw, P. A., Choi, G. H., Aqui, N., Fesnak, A., Yang, J. B., Soto-Calderon, H., Grajales, L., Starr, J., Andronov, M., Mastellone, M., Amonu, C., Feret, G., DeMarshall, M., Buchanan, M., Caturla, M., Gordon, J., Wanicur, A., Monroy, M. A., Mampe, F., Lindemuth, E., Gouma, S., Mullin, A. M., Barilla, H., Pronina, A., Irwin, L., Thomas, R., Eichinger, R. A., Demuth, F., Luning Prak, E. T., Pascual, J. L., Short, W. R., Elovitz, M. A., Baron, J., Meyer, N. J., Degnan, K. O., Frank, I., Hensley, S. E., Siegel, D. L., Tebas, P.: A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest 131(24), December 2021.

back to top
Last updated: 03/25/2022
The Trustees of the University of Pennsylvania